Generic Name and Formulations:
Antazoline phosphate 0.5%, naphazoline HCl 0.05%; oph. soln; contains benzalkonium chloride.
- DMTs Do Not Moderate Disability in Patients With MS and Diabetes, Other Comorbidities
- Glatiramer Acetate Associated With Long-Term Disability Improvements in MS
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
Indications for VASOCON-A:
Temporary relief of ocular redness and itching.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 1–2 drops up to 4 times daily.
Narrow-angle glaucoma. Concurrent MAOIs. Contact lens wear.
Avoid prolonged use. Hypertension. Cardiovascular disease. Urinary hesitancy. Diabetes. Pregnancy. Nursing mothers.
Hypertensive crisis with MAOIs.
Mydriasis, increased IOP, local irritation, allergic dermatitis, sensitization, systemic effects if absorbed, may precipitate narrow-angle glaucoma.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL